RayzeBio
Manufacturing · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
5505 Morehouse Dr Ste 300, San Diego, Ca...Phone Number
(619) 937-2754Website
www.rayzebio.comRevenue
$65.5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
2
1
1
1
1
About RayzeBio
RayzeBio is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. With a focus on clinically validated solid tumor targets, RayzeBio is developing novel drug conjugates to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter. The company is backed by a syndicate of sophisticated healthcare investors and was established in 2020.Explore more
RayzeBio Org Chart
PH
Head Executive Director, Msls & Medical Affai...
LG
Senior Director, Clinical Scientist
ES
Senior Director, Radiation Biophysics and Nuc...
SL
Director of Molecular Imaging
KN
Director, Medical Affairs Research Operations
RM
Regional Director, Medical Science Liaisons (...
PJ
Senior Medical Director
BW
Associate Director, Clinical Operations
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is RayzeBio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Click to see if RayzeBio had a recent Job posting/layoffs
Funding: Get notified immidiatlly once RayzeBio has new funding data
Product Launch: Get notified when RayzeBio launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at RayzeBio
RayzeBio, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on RayzeBio recently announced quarterly report
Check out if RayzeBio is spiking on competitors!
Check if RayzeBio has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to RayzeBio
Compare insights from companies similar to RayzeBio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
RayzeBio
$65.5M
201-500
Private
$418M
2020
SC
Sudhakar ChintharlapalliVice President, Head of Biology, Pharmacology and Translational
Company Profile Activity
Activity Insights
RayzeBio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
RayzeBio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about RayzeBio.
RayzeBio financials insights
Gather financial insights about RayzeBio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$45M
Series B
$105M
2021
Series C
$108M
2022
Series D
$160M
RayzeBio Tech Stack
A closer look at the technologies used by RayzeBio
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
RayzeBio News & Media
venBio Partners LLC Makes New $114.51 Million Investment in RayzeBio, Inc. (NASDAQ:RYZB)
venBio Partners LLC acquired a new stake in RayzeBio, Inc. (NASDAQ:RYZB - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 5,158,162 shares of the company's stock, valued at approximately $114,511,Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) announced today that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ: RYZB). With the completion of the acquisition, RayzeBio shares have ceased trading on the NASDAQ Global Market and RayzeBio is now a wholly owned subsidiary of Bristol Myers Squibb. “We are excited to complete this transaction, which adds radiopharmaceutical therapeutics (RPTs), one of the fastest-growing new modalities for treating pat
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding RayzeBio
Sign Up For FreeTo access detailed company insights
RayzeBio is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. With a focus on clinically validated solid tumor targets, RayzeBio is developing novel drug conjugates to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter. The company is backed b... Read More
